Lawyer Warns Against Launching Unauthorized Peptide Companies in Canada

A Toronto law firm is warning entrepreneurs that starting a peptide business in Canada without Health Canada approvals can trigger seizures, recalls, prosecution and other enforcement actions. The warning comes as demand for peptides grows and regulators step up scrutiny of unauthorized health products.

Why it matters: - Peptide businesses that skip federal approvals face legal exposure, product enforcement and possible criminal penalties in Canada. - Health Canada treats unauthorized peptide products as a public safety issue because their safety, efficacy and quality have not been reviewed. - Entrepreneurs entering the market can lose time, capital and inventory if products are found to be non-compliant.

What happened: - Substance Law issued a warning on June 23, 2026, from Toronto about the risks of starting a peptide company without Health Canada authorization. - Harrison Jordan, founder and managing lawyer at Substance Law, said rising interest in peptides has created a legal environment where entrepreneurial enthusiasm collides with federal health rules. - The firm is offering consultations to help prospective businesses understand the approvals needed to operate legally in Canada.

The details: - Under the Food and Drugs Act, products manufactured, sold or represented for diagnosing, treating, mitigating or preventing disease, disorder or abnormal physical state can be classified as drugs or natural health products. - Peptides generally fall under those classifications and require pre-market review and authorization before sale in Canada. - Health Canada has warned that unauthorized peptide products have not been evaluated for safety, efficacy or quality. - Health Canada can order product seizures, mandatory recalls, public advisories and referrals for federal criminal prosecution. - Health Canada inspectors can enter premises, examine records and seize materials suspected of violating the Act, subject to specific exceptions. - More serious cases can lead to substantial fines and possible imprisonment for companies and personnel. - Substance Law says lawful operation may require a Drug Establishment Licence, which covers manufacturing, packaging, labeling or importing health products. - Product-specific approvals such as Drug Identification Numbers, or DINs, may also be required. - The firm said some unauthorized operators label products "not for human consumption" or "for research purposes only" while still marketing them to consumers for physical use. - Health Canada looks at overall product representation, including marketing and intended use, rather than relying only on package disclaimers. - Harrison Jordan said Health Canada approvals are not optional and are a fundamental legal prerequisite for doing business in the sector. - A compliant peptide business may need clinical data, detailed manufacturing protocols, quality assurance testing and strict Good Manufacturing Practices covering sanitation, training and record-keeping. - Substance Law said those requirements create a realistic barrier to entry for would-be market participants.

Between the lines: - The warning signals a broader shift from consumer curiosity about peptides to a more regulated commercial environment. - Online sales and broad marketing claims appear to be drawing sharper enforcement attention as Health Canada responds to emerging market trends. - Businesses that frame products as research-only may still face enforcement if the real-world marketing suggests consumer use.

What's next: - Substance Law plans to keep updating its educational materials as federal enforcement and compliance guidance evolve. - The firm expects Health Canada oversight of health products to become more stringent as unauthorized substances continue to circulate online. - Prospective entrants will need to weigh approval timelines, scientific support and compliance costs before launching any peptide-related business.

The bottom line: - In Canada, peptide businesses are not a regulatory gray area; they are a licensing and compliance test before they can legally sell to consumers.

More information: Substance Law